2021 Q3 Form 10-Q Financial Statement
#000086266821000018 Filed on November 15, 2021
Income Statement
Concept | 2021 Q3 | 2020 Q3 |
---|---|---|
Revenue | $2.675M | $2.414M |
YoY Change | 10.82% | 5.5% |
Cost Of Revenue | $1.664M | $1.504M |
YoY Change | 10.64% | 27.81% |
Gross Profit | $1.011M | $909.9K |
YoY Change | 11.13% | -18.12% |
Gross Profit Margin | 37.8% | 37.7% |
Selling, General & Admin | $904.5K | $892.2K |
YoY Change | 1.38% | -10.73% |
% of Gross Profit | 89.45% | 98.05% |
Research & Development | $291.2K | $209.3K |
YoY Change | 39.11% | -14.78% |
% of Gross Profit | 28.8% | 23.0% |
Depreciation & Amortization | $13.45K | $11.30K |
YoY Change | 18.99% | -5.06% |
% of Gross Profit | 1.33% | 1.24% |
Operating Expenses | $1.196M | $1.101M |
YoY Change | 8.55% | -11.53% |
Operating Profit | -$184.5K | -$191.6K |
YoY Change | -3.7% | 43.24% |
Interest Expense | $4.697K | $5.518K |
YoY Change | -14.88% | 38.5% |
% of Operating Profit | ||
Other Income/Expense, Net | $501.7K | -$4.979K |
YoY Change | -10176.42% | -100.66% |
Pretax Income | $317.2K | -$196.6K |
YoY Change | -261.39% | -131.63% |
Income Tax | ||
% Of Pretax Income | ||
Net Earnings | $317.2K | -$196.6K |
YoY Change | -261.39% | -131.63% |
Net Earnings / Revenue | 11.86% | -8.14% |
Basic Earnings Per Share | $0.04 | -$0.03 |
Diluted Earnings Per Share | $0.02 | -$0.03 |
COMMON SHARES | ||
Basic Shares Outstanding | 7.415M shares | 7.415M shares |
Diluted Shares Outstanding | 12.88M shares | 7.415M shares |
Balance Sheet
Concept | 2021 Q3 | 2020 Q3 |
---|---|---|
SHORT-TERM ASSETS | ||
Cash & Short-Term Investments | $1.256M | $1.366M |
YoY Change | -8.06% | 228.5% |
Cash & Equivalents | $1.256M | $1.366M |
Short-Term Investments | ||
Other Short-Term Assets | $195.9K | $178.8K |
YoY Change | 9.56% | -21.45% |
Inventory | $1.388M | $1.585M |
Prepaid Expenses | ||
Receivables | $1.358M | $1.046M |
Other Receivables | $0.00 | $0.00 |
Total Short-Term Assets | $4.453M | $4.431M |
YoY Change | 0.51% | 6.7% |
LONG-TERM ASSETS | ||
Property, Plant & Equipment | $72.91K | $90.82K |
YoY Change | -19.73% | 49.13% |
Goodwill | ||
YoY Change | ||
Intangibles | ||
YoY Change | ||
Long-Term Investments | ||
YoY Change | ||
Other Assets | $62.79K | $62.79K |
YoY Change | 0.0% | 0.0% |
Total Long-Term Assets | $1.008M | $1.312M |
YoY Change | -23.19% | -31.69% |
TOTAL ASSETS | ||
Total Short-Term Assets | $4.453M | $4.431M |
Total Long-Term Assets | $1.008M | $1.312M |
Total Assets | $5.461M | $5.743M |
YoY Change | -4.91% | -5.44% |
SHORT-TERM LIABILITIES | ||
YoY Change | ||
Accounts Payable | $1.122M | $919.6K |
YoY Change | 21.99% | 33.01% |
Accrued Expenses | $793.1K | $814.1K |
YoY Change | -2.57% | 31.42% |
Deferred Revenue | ||
YoY Change | ||
Short-Term Debt | $204.5K | $201.6K |
YoY Change | 1.43% | 0.0% |
Long-Term Debt Due | $3.400K | $3.490K |
YoY Change | -2.58% | 0.0% |
Total Short-Term Liabilities | $2.911M | $3.191M |
YoY Change | -8.79% | 31.22% |
LONG-TERM LIABILITIES | ||
Long-Term Debt | $158.9K | $354.9K |
YoY Change | -55.23% | 2438.77% |
Other Long-Term Liabilities | $40.86K | $881.8K |
YoY Change | -95.37% | 4.43% |
Total Long-Term Liabilities | $773.8K | $1.237M |
YoY Change | -37.44% | 44.07% |
TOTAL LIABILITIES | ||
Total Short-Term Liabilities | $2.911M | $3.191M |
Total Long-Term Liabilities | $773.8K | $1.237M |
Total Liabilities | $3.684M | $4.428M |
YoY Change | -16.79% | 34.57% |
SHAREHOLDERS EQUITY | ||
Retained Earnings | -$68.60M | -$69.04M |
YoY Change | -0.64% | 2.17% |
Common Stock | $7.415K | $7.415K |
YoY Change | 0.0% | 0.0% |
Preferred Stock | ||
YoY Change | ||
Treasury Stock (at cost) | ||
YoY Change | ||
Treasury Stock Shares | ||
Shareholders Equity | $1.777M | $1.315M |
YoY Change | ||
Total Liabilities & Shareholders Equity | $5.461M | $5.743M |
YoY Change | -4.91% | -5.44% |
Cashflow Statement
Concept | 2021 Q3 | 2020 Q3 |
---|---|---|
OPERATING ACTIVITIES | ||
Net Income | $317.2K | -$196.6K |
YoY Change | -261.39% | -131.63% |
Depreciation, Depletion And Amortization | $13.45K | $11.30K |
YoY Change | 18.99% | -5.06% |
Cash From Operating Activities | -$393.4K | $541.1K |
YoY Change | -172.7% | 7450.64% |
INVESTING ACTIVITIES | ||
Capital Expenditures | ||
YoY Change | ||
Acquisitions | ||
YoY Change | ||
Other Investing Activities | ||
YoY Change | ||
Cash From Investing Activities | $0.00 | |
YoY Change | ||
FINANCING ACTIVITIES | ||
Cash Dividend Paid | ||
YoY Change | ||
Common Stock Issuance & Retirement, Net | ||
YoY Change | ||
Debt Paid & Issued, Net | ||
YoY Change | ||
Cash From Financing Activities | -$1.663K | -$889.00 |
YoY Change | 87.06% | 8.15% |
NET CHANGE | ||
Cash From Operating Activities | -$393.4K | $541.1K |
Cash From Investing Activities | $0.00 | |
Cash From Financing Activities | -$1.663K | -$889.00 |
Net Change In Cash | -$395.0K | $540.2K |
YoY Change | -173.13% | 8414.97% |
FREE CASH FLOW | ||
Cash From Operating Activities | -$393.4K | $541.1K |
Capital Expenditures | ||
Free Cash Flow | ||
YoY Change |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2021Q3 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2021-09-30 | |
CY2021Q3 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2022 | |
CY2021Q3 | dei |
Entity Registrant Name
EntityRegistrantName
|
Escalon Medical Corp. | |
CY2021Q3 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0000862668 | |
CY2021Q3 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--06-30 | |
CY2021Q3 | dei |
Document Type
DocumentType
|
10-Q | |
CY2021Q3 | dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | |
CY2021Q3 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
CY2021Q3 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2021Q3 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
CY2021Q3 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
CY2021Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1255824 | USD |
CY2021Q3 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2021Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
7415329 | shares |
CY2021Q3 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2021Q3 | dei |
Entity File Number
EntityFileNumber
|
000-20127 | |
CY2021Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2020Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2021Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
35000000 | shares |
CY2020Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
35000000 | shares |
CY2021Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
7415329 | shares |
CY2020Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
7415329 | shares |
CY2021Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
7415329 | shares |
CY2020Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
7415329 | shares |
CY2021Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2020Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2021Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
2000000 | shares |
CY2020Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
2000000 | shares |
CY2021Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
2000000 | shares |
CY2020Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
2000000 | shares |
CY2021Q3 | dei |
Document Type
DocumentType
|
10-Q | |
CY2021Q3 | dei |
Entity Registrant Name
EntityRegistrantName
|
Escalon Medical Corp. | |
CY2021Q3 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
PA | |
CY2021Q3 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
33-0272839 | |
CY2021Q3 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
435 Devon Park Drive | |
CY2021Q3 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Wayne | |
CY2021Q3 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
PA | |
CY2021Q3 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
19087 | |
CY2021Q3 | dei |
City Area Code
CityAreaCode
|
(610) | |
CY2021Q3 | dei |
Local Phone Number
LocalPhoneNumber
|
688-6830 | |
CY2021Q3 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2021Q3 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2021Q3 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
CY2021Q3 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
CY2021Q3 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
CY2021Q3 | dei |
Security12b Title
Security12bTitle
|
common stock, $0.001 par value | |
CY2021Q2 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
102400 | USD |
CY2021Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1650970 | USD |
CY2021Q3 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
256017 | USD |
CY2021Q2 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
255920 | USD |
CY2021Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
1357850 | USD |
CY2021Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
1081702 | USD |
CY2021Q3 | us-gaap |
Inventory Net
InventoryNet
|
1387798 | USD |
CY2021Q2 | us-gaap |
Inventory Net
InventoryNet
|
1416727 | USD |
CY2021Q3 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
195908 | USD |
CY2021Q2 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
187357 | USD |
CY2021Q3 | us-gaap |
Assets Current
AssetsCurrent
|
4453397 | USD |
CY2021Q2 | us-gaap |
Assets Current
AssetsCurrent
|
4592676 | USD |
CY2021Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
72905 | USD |
CY2021Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
81442 | USD |
CY2021Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
774841 | USD |
CY2021Q2 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
843559 | USD |
CY2021Q3 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
97487 | USD |
CY2021Q3 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
276268 | USD |
CY2021Q3 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
62789 | USD |
CY2021Q2 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
62789 | USD |
CY2021Q3 | us-gaap |
Assets
Assets
|
5461419 | USD |
CY2021Q2 | us-gaap |
Assets
Assets
|
5682866 | USD |
CY2021Q3 | us-gaap |
Lines Of Credit Current
LinesOfCreditCurrent
|
201575 | USD |
CY2021Q2 | us-gaap |
Lines Of Credit Current
LinesOfCreditCurrent
|
201575 | USD |
CY2021Q3 | us-gaap |
Other Notes Payable Current
OtherNotesPayableCurrent
|
3401 | USD |
CY2021Q2 | us-gaap |
Other Notes Payable Current
OtherNotesPayableCurrent
|
3401 | USD |
CY2021Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1121742 | USD |
CY2021Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1102125 | USD |
CY2021Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
793142 | USD |
CY2021Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
695553 | USD |
CY2021Q3 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
112389 | USD |
CY2021Q2 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
112389 | USD |
CY2021Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
265101 | USD |
CY2021Q2 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
279051 | USD |
CY2021Q2 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
363700 | USD |
CY2021Q3 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
134007 | USD |
CY2021Q2 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
136107 | USD |
CY2021Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2910513 | USD |
CY2021Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
3396763 | USD |
CY2021Q3 | us-gaap |
Other Long Term Notes Payable
OtherLongTermNotesPayable
|
6881 | USD |
CY2021Q2 | us-gaap |
Other Long Term Notes Payable
OtherLongTermNotesPayable
|
7839 | USD |
CY2021Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
573977 | USD |
CY2021Q2 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
630330 | USD |
CY2021Q3 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
40860 | USD |
CY2021Q2 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
40860 | USD |
CY2021Q3 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
773750 | USD |
CY2021Q2 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
826167 | USD |
CY2021Q3 | us-gaap |
Liabilities
Liabilities
|
3684263 | USD |
CY2021Q2 | us-gaap |
Liabilities
Liabilities
|
4222930 | USD |
CY2021Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
645000 | USD |
CY2021Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
645000 | USD |
CY2021Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
7415 | USD |
CY2021Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
7415 | USD |
CY2021Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
69702043 | USD |
CY2021Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
69702043 | USD |
CY2021Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-68577302 | USD |
CY2021Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-68894522 | USD |
CY2021Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1777156 | USD |
CY2021Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1459936 | USD |
CY2021Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
5461419 | USD |
CY2021Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
5682866 | USD |
CY2021Q3 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
2675069 | USD |
CY2020Q3 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
2413794 | USD |
CY2021Q3 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
1663874 | USD |
CY2020Q3 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
1503869 | USD |
CY2021Q3 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
904491 | USD |
CY2020Q3 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
892177 | USD |
CY2021Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
291189 | USD |
CY2020Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
209322 | USD |
CY2021Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
2859554 | USD |
CY2020Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
2605368 | USD |
CY2021Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-184485 | USD |
CY2020Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-191574 | USD |
CY2021Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
506305 | USD |
CY2020Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
0 | USD |
CY2021Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
97 | USD |
CY2020Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
539 | USD |
CY2021Q3 | us-gaap |
Interest Expense
InterestExpense
|
4697 | USD |
CY2020Q3 | us-gaap |
Interest Expense
InterestExpense
|
5518 | USD |
CY2021Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
501705 | USD |
CY2020Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-4979 | USD |
CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
317220 | USD |
CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-196553 | USD |
CY2021Q3 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
13006 | USD |
CY2020Q3 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
12970 | USD |
CY2021Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
304214 | USD |
CY2020Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-209523 | USD |
CY2021Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.04 | |
CY2020Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.03 | |
CY2021Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.02 | |
CY2020Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.03 | |
CY2021Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
7415329 | shares |
CY2020Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
7415329 | shares |
CY2021Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
12876202 | shares |
CY2020Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
7415329 | shares |
CY2021Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1459936 | USD |
CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
317220 | USD |
CY2021Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1777156 | USD |
CY2020Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1511959 | USD |
CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-196553 | USD |
CY2020Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1315406 | USD |
CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
317220 | USD |
CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
317220 | USD |
CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-196553 | USD |
CY2021Q3 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
15000 | USD |
CY2020Q3 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
0 | USD |
CY2021Q3 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-506305 | USD |
CY2020Q3 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
0 | USD |
CY2021Q3 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
13450 | USD |
CY2020Q3 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
11303 | USD |
CY2021Q3 | us-gaap |
Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
|
68718 | USD |
CY2020Q3 | us-gaap |
Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
|
74310 | USD |
CY2021Q3 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
291148 | USD |
CY2020Q3 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-267398 | USD |
CY2021Q3 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-28929 | USD |
CY2020Q3 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-200069 | USD |
CY2021Q3 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
8551 | USD |
CY2020Q3 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
24630 | USD |
CY2021Q3 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
19617 | USD |
CY2020Q3 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
158946 | USD |
CY2021Q3 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
109519 | USD |
CY2020Q3 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
133015 | USD |
CY2021Q3 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-70303 | USD |
CY2020Q3 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-73754 | USD |
CY2021Q3 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-87432 | USD |
CY2020Q3 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-48553 | USD |
CY2021Q3 | us-gaap |
Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
|
-2100 | USD |
CY2020Q3 | us-gaap |
Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
|
39528 | USD |
CY2021Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-393386 | USD |
CY2020Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
541079 | USD |
CY2021Q3 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
958 | USD |
CY2020Q3 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
889 | USD |
CY2022Q1 | esmc |
Repayment Of Eidl Loan
RepaymentOfEIDLLoan
|
-705 | USD |
CY2020Q3 | esmc |
Repayment Of Eidl Loan
RepaymentOfEIDLLoan
|
0 | USD |
CY2021Q3 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-1663 | USD |
CY2020Q3 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-889 | USD |
CY2021Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-395049 | USD |
CY2020Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
540190 | USD |
CY2021Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
1906890 | USD |
CY2020Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
1081239 | USD |
CY2021Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
1511841 | USD |
CY2020Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
1621429 | USD |
CY2021Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1255824 | USD |
CY2020Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1365954 | USD |
CY2021Q3 | us-gaap |
Restricted Cash
RestrictedCash
|
256017 | USD |
CY2020Q3 | us-gaap |
Restricted Cash
RestrictedCash
|
255475 | USD |
CY2021Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
1511841 | USD |
CY2020Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
1621429 | USD |
CY2021Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1650970 | USD |
CY2020Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
825958 | USD |
CY2021Q2 | us-gaap |
Restricted Cash
RestrictedCash
|
255920 | USD |
CY2020Q2 | us-gaap |
Restricted Cash
RestrictedCash
|
255281 | USD |
CY2021Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
1906890 | USD |
CY2020Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
1081239 | USD |
CY2021Q3 | us-gaap |
Interest Paid Net
InterestPaidNet
|
4697 | USD |
CY2020Q3 | us-gaap |
Interest Paid Net
InterestPaidNet
|
2854 | USD |
CY2021Q3 | esmc |
Record Ro Uassets
RecordROUassets
|
0 | USD |
CY2020Q3 | esmc |
Record Ro Uassets
RecordROUassets
|
18001 | USD |
CY2021Q3 | esmc |
Record Lease Liabilities
RecordLeaseLiabilities
|
0 | USD |
CY2020Q3 | esmc |
Record Lease Liabilities
RecordLeaseLiabilities
|
18001 | USD |
CY2021Q3 | esmc |
Dispose Ro Uassets
DisposeROUassets
|
0 | USD |
CY2020Q3 | esmc |
Dispose Ro Uassets
DisposeROUassets
|
9154 | USD |
CY2021Q3 | esmc |
Dispose Lease Liabilities
DisposeLeaseLiabilities
|
0 | USD |
CY2020Q3 | esmc |
Dispose Lease Liabilities
DisposeLeaseLiabilities
|
9154 | USD |
CY2020Q2 | us-gaap |
Nature Of Operations
NatureOfOperations
|
Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the “Company” collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (“Sonomed”), Escalon Digital Solutions, Inc. (“EMI”), and Sonomed IP Holdings, Inc. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the “FDA”). The FDA and other government authorities require extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The unaudited condensed consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, and reflect all adjustments (consisting of only normal and recurring adjustments) which are, in the opinion of management, necessary to present fairly the unaudited condensed consolidated financial information required herein. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United Statements of America ("US GAAP") have been condensed or omitted pursuant to such rules and regulations. While management believes that the disclosures are adequate to make the information presented not misleading, it is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K filed with the Security and Exchange Commission for the fiscal year ended June 30, 2021. The results of operations for the three months ended September 30, 2021 are not necessarily indicative of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the results to be expected for the full year. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> On March 11, 2020, the World Health Organization declared the outbreak of a coronavirus (COVID-19) a pandemic. This pandemic has had a significant impact on the global and domestic economy, and is likely to impact the operations of the Company. The Company has been assessing the impact of the COVID-19 pandemic on the business, including the impact on the financial condition and results of operations, financial resources, changes in accounting judgment as well as the impact on the supply and demand, etc. The Company is considered an essential business and was able to maintain operations during the lockdown. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">However, the Company does not know the extent and duration of the impact of COVID-19 on its business due to the uncertainty about the spread of the virus. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company applied for and received $500,000 in April 2020 under the Payroll Protection Program (PPP loan) which helped reverse the negative impact in terms of the liquidity. The maturity date was two years from the date of the note. The interest rate was 1.00% per year. The full amount of the PPP loan and accrued interest were forgiven on August 13, 2021 a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nd was included in other income in the unaudited condensed consolidated statement of operations for the three-month period ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The Company received a $150,000 Economic Injury Disaster ("EIDL") loan. The annual interest rate is 3.75%.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The payment term is 30 years and the monthly payment of $731 started on July 1, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company’s common stock trades on the OTCQB Market under the symbol “ESMC.”</span></div> | |
CY2021Q3 | esmc |
Pp Ploanamount
PPPloanamount
|
500000 | USD |
CY2021Q3 | us-gaap |
Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
|
0.0100 | |
CY2021Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-68600000 | USD |
CY2021Q3 | us-gaap |
Use Of Estimates
UseOfEstimates
|
The preparation of financial statements in conformity with accounting principles generally affected in the US Generally Accepted Accounting Principles ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. | |
CY2021Q3 | esmc |
Maximum Maturity Of Highly Liquid Investments Period
MaximumMaturityOfHighlyLiquidInvestmentsPeriod
|
P90D | |
CY2021Q3 | us-gaap |
Restricted Cash
RestrictedCash
|
256000 | USD |
CY2021Q2 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
115000 | USD |
CY2020Q2 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
100000 | USD |
CY2021 | us-gaap |
Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
|
0 | USD |
CY2020Q3 | us-gaap |
Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
|
230000 | USD |
CY2021Q3 | us-gaap |
Deferred Revenue
DeferredRevenue
|
276000 | USD |
CY2020Q3 | us-gaap |
Deferred Revenue
DeferredRevenue
|
467000 | USD |
CY2021Q2 | us-gaap |
Deferred Revenue
DeferredRevenue
|
364000 | USD |
CY2020Q2 | us-gaap |
Deferred Revenue
DeferredRevenue
|
516000 | USD |
CY2021Q3 | us-gaap |
Deferred Revenue Additions
DeferredRevenueAdditions
|
107000 | USD |
CY2020Q3 | us-gaap |
Deferred Revenue Additions
DeferredRevenueAdditions
|
181000 | USD |
CY2021Q3 | us-gaap |
Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
|
195000 | USD |
CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
317220 | USD |
CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
317220 | USD |
CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-196553 | USD |
CY2021Q3 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
13006 | USD |
CY2020Q3 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
12970 | USD |
CY2021Q3 | us-gaap |
Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
|
304214 | USD |
CY2020Q3 | us-gaap |
Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
|
-209523 | USD |
CY2021Q3 | us-gaap |
Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
|
304214 | USD |
CY2020Q3 | us-gaap |
Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
|
-209523 | USD |
CY2021Q3 | us-gaap |
Convertible Preferred Dividends Net Of Tax
ConvertiblePreferredDividendsNetOfTax
|
13006 | USD |
CY2020Q3 | us-gaap |
Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
|
0 | USD |
CY2021Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
317220 | USD |
CY2020Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-209523 | USD |
CY2021Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
7415329 | shares |
CY2020Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
7415329 | shares |
CY2021Q3 | us-gaap |
Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
|
5460873 | shares |
CY2020Q3 | us-gaap |
Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
|
0 | shares |
CY2021Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
12876202 | shares |
CY2020Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
7415329 | shares |
CY2021Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.04 | |
CY2020Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.03 | |
CY2021Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.02 | |
CY2020Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.03 | |
CY2021Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
157000 | shares |
CY2020Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5361527 | shares |
CY2021Q3 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
852000 | USD |
CY2021Q2 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
833000 | USD |
CY2021Q3 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
134000 | USD |
CY2021Q2 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
171000 | USD |
CY2021Q3 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
752000 | USD |
CY2021Q2 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
773000 | USD |
CY2021Q3 | us-gaap |
Inventory Gross
InventoryGross
|
1738000 | USD |
CY2021Q2 | us-gaap |
Inventory Gross
InventoryGross
|
1777000 | USD |
CY2021Q3 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
350000 | USD |
CY2021Q2 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
360000 | USD |
CY2021Q3 | us-gaap |
Inventory Net
InventoryNet
|
1388000 | USD |
CY2021Q2 | us-gaap |
Inventory Net
InventoryNet
|
1417000 | USD |
CY2018Q1 | us-gaap |
Related Party Transaction Due From To Related Party
RelatedPartyTransactionDueFromToRelatedParty
|
645000 | USD |
CY2018Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
2000000 | shares |
CY2021Q3 | us-gaap |
Common Stock Voting Rights
CommonStockVotingRights
|
77.81 | |
CY2021Q1 | us-gaap |
Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
|
2.15 | shares |
CY2021Q3 | us-gaap |
Common Stock Conversion Basis
CommonStockConversionBasis
|
4,300,000 | |
CY2021Q3 | us-gaap |
Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
|
0.3670 | |
CY2018Q1 | us-gaap |
Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
|
0.0258 | |
CY2021Q3 | us-gaap |
Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
|
187137 | USD |
CY2021Q3 | us-gaap |
Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
|
0.0936 | |
CY2020Q3 | us-gaap |
Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
|
174131 | USD |
CY2020Q3 | us-gaap |
Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
|
0.0871 | |
CY2021Q1 | us-gaap |
Line Of Credit Facility Interest Rate At Period End
LineOfCreditFacilityInterestRateAtPeriodEnd
|
0.0099 | |
CY2021Q3 | us-gaap |
Lines Of Credit Current
LinesOfCreditCurrent
|
201575 | USD |
CY2021Q3 | us-gaap |
Line Of Credit Facility Periodic Payment Interest
LineOfCreditFacilityPeriodicPaymentInterest
|
3000 | USD |
CY2020Q3 | us-gaap |
Line Of Credit Facility Periodic Payment Interest
LineOfCreditFacilityPeriodicPaymentInterest
|
3000 | USD |
CY2021Q3 | us-gaap |
Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
|
731 | USD |
CY2021Q3 | us-gaap |
Other Long Term Debt
OtherLongTermDebt
|
82000 | USD |
CY2021Q3 | us-gaap |
Other Short Term Borrowings
OtherShortTermBorrowings
|
41000 | USD |
CY2021Q3 | us-gaap |
Concentration Risk Supplier
ConcentrationRiskSupplier
|
three | |
CY2021 | us-gaap |
Concentration Risk Supplier
ConcentrationRiskSupplier
|
three | |
CY2021Q3 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
84245 | USD |
CY2020Q3 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
93861 | USD |
CY2021Q3 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
84245 | USD |
CY2020Q3 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
93861 | USD |
CY2021Q3 | us-gaap |
Short Term Lease Payments
ShortTermLeasePayments
|
82390 | USD |
CY2020Q3 | us-gaap |
Short Term Lease Payments
ShortTermLeasePayments
|
89800 | USD |
CY2021Q3 | us-gaap |
Short Term Lease Payments
ShortTermLeasePayments
|
82390 | USD |
CY2020Q3 | us-gaap |
Short Term Lease Payments
ShortTermLeasePayments
|
89800 | USD |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
239133 | USD |
CY2021Q3 | us-gaap |
Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
|
263162 | USD |
CY2021Q3 | us-gaap |
Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
|
268372 | USD |
CY2021Q3 | us-gaap |
Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
|
141865 | USD |
CY2021Q3 | us-gaap |
Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
|
2728 | USD |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
915260 | USD |
CY2021Q3 | esmc |
Interestportioninthefutureleasepayments
Interestportioninthefutureleasepayments
|
76182 | USD |
CY2021Q3 | esmc |
Netpresentvalueofnewleasefuturepayments
Netpresentvalueofnewleasefuturepayments
|
839078 | USD |
CY2021Q3 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P3Y1M24D | |
CY2021Q2 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P3Y4M6D | |
CY2021Q3 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0565 | |
CY2021Q2 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0565 |